Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Takahiko Kasai
Based on 2 articles published since 2009
(Why 2 articles?)
||||

Between 2009 and 2019, Takahiko Kasai wrote the following 2 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Article Prognostic significance of WNT signaling in pancreatic ductal adenocarcinoma. 2014

Nakamoto, Mitsuhiro / Matsuyama, Atsuji / Shiba, Eisuke / Shibuya, Ryo / Kasai, Takahiko / Yamaguchi, Koji / Hisaoka, Masanori. ·Department of Pathology and Oncology, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8555, Japan. ·Virchows Arch · Pubmed #25146168.

ABSTRACT: Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal human malignancies and is associated with a variety of molecular abnormalities. Although WNT signaling through its canonical/non-canonical pathways is one of the major factors involved in oncogenesis or progression of PDA, the prognostic significance of WNT signaling still remains poorly investigated. In this study, the status of the WNT signaling pathways was immunohistochemically analyzed in 101 PDAs, and its potential association with patient postoperative survival was assessed. Nuclear expression of beta-catenin, a hallmark of the activated canonical pathway, was identified in 59 cases, and was associated with reduced survival compared to the patients lacking nuclear beta-catenin expression (P = 0.002). In contrast, activation of the non-canonical pathway (25 cases), as indicated by co-expression of WNT2/5a and nuclear NFATc1, was not correlated with reduced survival (P = 0.268). Co-activation of both pathways (16 cases) was associated with worse prognosis in comparison with cases with an activated non-canonical pathway (P = 0.034). In addition, nuclear beta-catenin expression was an independent unfavorable prognostic factor (P = 0.006). Our data indicate that activated WNT signaling through its canonical pathway has a significantly negative effect on the clinical course of PDA, and the canonical WNT pathway should be considered as a future therapeutic target for PDA.

2 Article Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer. 2013

Sho, Masayuki / Akahori, Takahiro / Tanaka, Toshihiro / Kinoshita, Shoichi / Tamamoto, Tetsuro / Nomi, Takeo / Yamato, Ichiro / Hokuto, Daisuke / Yasuda, Satoshi / Kawaguchi, Chihiro / Nishiofuku, Hideyuki / Marugami, Nagaaki / Enomonoto, Yasunori / Kasai, Takahiko / Hasegawa, Masatoshi / Kichikawa, Kimihiko / Nakajima, Yoshiyuki. ·Department of Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan. m-sho@naramed-u.ac.jp ·J Hepatobiliary Pancreat Sci · Pubmed #22766692.

ABSTRACT: BACKGROUND/PURPOSE: The therapeutic options available as preoperative strategies for resectable pancreatic cancer have received worldwide attention. We have recently introduced neoadjuvant chemoradiotherapy (NACRT) to achieve local control and possibly complete cure. In this study, we have retrospectively evaluated its impact on pathology and the perioperative clinical course in addition to its safety. METHODS: Sixty-one patients who received full-dose gemcitabine (1000 mg/m(2)) preoperatively with concurrent radiation (50 or 54 Gy) were evaluated. Seventy-one patients who received no preoperative therapy served as controls. Perioperative outcomes, postoperative complications, immunonutritional status, and the performance of adjuvant chemotherapy were compared. RESULTS: Fifty-nine patients (97 %) completed NACRT. Toxicity was acceptable and the regimen was feasible as outpatient treatment. The perioperative outcomes were closely comparable to control. The rate of pancreatic fistula was lower and hospital stay was shorter in the NACRT group. The rate of lymph node metastasis and stage was lower in the NACRT group. Furthermore, R0 resection could be achieved in 92 % of patients treated with NACRT. Nutritional status decreased after NACRT and further deteriorated during adjuvant chemotherapy. The initiation of postoperative chemotherapy was delayed in the NACRT group. CONCLUSIONS: Our current protocol of neoadjuvant chemoradiotherapy is feasible and substantially improves the pathology. However, it has some detrimental effects on postoperative nutritional status and performance of adjuvant chemotherapy. Furthermore, it should be noted that there is a possibility of arterial complications.